^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

APC activator

1d
Enrollment closed • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • PGR positive
|
paclitaxel • ImmuFact (eftilagimod alpha)
9d
New P3 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed • ImmuFact (eftilagimod alpha)
2ms
TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative (ESMO-IO 2024)
Table: 152P RECIST 1.1 N=31 iRECIST N=31 Complete response (%) 9.7 9.7 Partial response (%) 25.8 29.0 Stable disease (%) 22.6 25.8 Progressive disease (%) 41.9 35.5 Overall Response Rate (ORR)* (%), [95% CI] 35.5, [19.2-54.6] 38.7, [21.8-57.8] Disease Control Rate (DCR) (%), [95% CI] 58.1, [39.1-75.5] 64.5, [45.4-80.8] *10/11 responses confirmed by RECIST 1.1 and 11/12 by iRECIST.Conclusions E + P leads to high ORR and DCR in a CPS negative pt population, which is typically unresponsive to P alone. Further late-stage clinical investigation is warranted for E+P in this disease setting.
Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
|
PD-L1 negative
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
2ms
Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity. (PubMed, Sci Transl Med)
OX40L-CAR-Tregs demonstrated an enhanced ability to control xenogeneic graft-versus-host disease compared with control Tregs without abolishing the graft-versus-leukemia effect. These results suggest that OX40L-CAR-Tregs may have wide applicability as a potent cellular therapy to control both allo- and autoimmune diseases.
Journal
|
FOXP3 (Forkhead Box P3) • TNFSF4 (TNF Superfamily Member 4)
2ms
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study. (PubMed, JTO Clin Res Rep)
Efti plus pembrolizumab was well-tolerated and revealed signs of antitumor activity in patients with NSCLC resistant to PD-(L)1 inhibitors, warranting further investigation. Trial registration number: NCT03625323.
P2 data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
5ms
Late-breaking abstract • P2b data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
5ms
Eftilagimod alpha (soluble LAG-3 protein) combined with pembrolizumab as second-line therapy for patients with metastatic head and neck squamous cell carcinoma. (PubMed, Clin Cancer Res)
Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in 2nd line HNSCC patients, thus supporting further evaluation of this combination in earlier treatment lines.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10)
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • ImmuFact (eftilagimod alpha)
6ms
GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation. (PubMed, Acta Pharmacol Sin)
Differentially expressed genes were found to be enriched in antigen processing process, specifically increased tumor infiltration of DCs, B1 cells and plasma cells in the OVA plus GFPBW1 group, in accordance with its activation and maturation function of APCs. Collectively, this study systematically describes the properties of GFPBW1 as a novel potent and safe adjuvant and highlights its great potential in vaccine development.
Journal
|
SYK (Spleen tyrosine kinase) • CLEC7A (C-Type Lectin Domain Containing 7A) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
12ms
Combination therapy • Trial completion date • IO biomarker • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
1year
New P2 trial • Combination therapy
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
1year
Combination therapy • Trial primary completion date • Enrollment closed • IO biomarker • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
1year
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase 2b Trial. (PubMed, Clin Cancer Res)
Although the primary endpoint, PFS, was not met, AIPAC confirmed expected pharmacodynamic effects and demonstrated excellent safety profile for efti. Overall survival was not significantly improved globally (2.9-month difference), but was significantly improved in exploratory biomarker subgroups, warranting further studies to clarify efti's role in patients with ET-resistant HER2- MBC.
P2b data • Journal • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
paclitaxel • ImmuFact (eftilagimod alpha)
1year
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology. (PubMed, ESMO Open)
Subcutaneously administered efti plus avelumab was well tolerated, and efti of 30 mg was determined to be RP2D. The activity is promising and warrants further investigation in future phase II trials.
P1 data • Journal • Immuno-oncology
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Bavencio (avelumab) • ImmuFact (eftilagimod alpha)
1year
Trial completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
1year
Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab (SITC 2023)
GEP analysis showed upregulated expression of genes related to T-cell functions, cytotoxicity functions, cytotoxic cells, or TH1 cells which are more pronounced in pts with PR/CR. Conclusions Significant early and sustained increases of circulating biomarkers and ALC substantiate the systemic stimulation via the APC activator efti and show that repeated minimally-invasive liquid biopsies, i. e. , blood samplings, are key in detecting this systemic stimulation.
PK/PD data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule)
|
CXCL10 expression
|
nCounter® PanCancer Immune Profiling Panel
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
over1year
Clinical • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3)
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
over1year
INSIGHT: Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors (clinicaltrials.gov)
P1, N=110, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | N=45 --> 110 | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2024 --> Sep 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
Bavencio (avelumab) • ImmuFact (eftilagimod alpha)
over1year
Combination therapy • Trial primary completion date • Metastases
|
CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
over1year
LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy. (PubMed, Biomedicines)
To date, two LAG-3-directed agents (eftilagimod alpha and relatlimab) have been approved in combination with programmed death-1 (PD-1) inhibitors in the setting of advanced solid tumors. In this review, we discuss the structure of LAG-3, its mechanism of action, and its interaction with its ligands. We also shed light on the emerging treatments targeting LAG-3 for the treatment of solid tumors.
Review • Journal • Checkpoint inhibition
|
LAG3 (Lymphocyte Activating 3)
|
ImmuFact (eftilagimod alpha) • relatlimab (BMS-986016)
over1year
Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial (ESMO 2023)
Correlation between tissue or blood-based biomarkers and clinical outcomes will be explored. Enrollment for the study is ongoing in Poland.
Clinical • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
LAG3 (Lymphocyte Activating 3)
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
over1year
INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas (ESMO 2023)
Methods Pts with 1st line advanced or metastatic NSCLC adenocarcinomas (non-squamous) receive carboplatin AUC5 / pemetrexed 500 mg/m2 q3w 4 cycles followed by optional pemetrexed 500 mg/m2 q3w maintenance plus pembrolizumab 200 mg q3w combined with s.c. efti (30 mg) (q2w for 24 weeks; thereafter q3w till week 52). Median follow up: 8.3 months, median OS: not reached. Conclusions To date, 30 mg efti combined with SOC appears to be feasible and safe with promising signals of efficacy, so that the trial was amended for inclusion of further 30 pts.
Clinical • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
|
PD-L1-L
|
Keytruda (pembrolizumab) • carboplatin • pemetrexed • ImmuFact (eftilagimod alpha)
over1year
Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II) (ESMO 2023)
Conclusions E + P shows encouraging OS results in line with excellent ORR, PFS and DOR in 1st line NSCLC overall and in all PD-L1 subgroups. This combination warrants further late-stage clinical investigation.
P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
over1year
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1. (ASCO 2023)
Sponsored by Pharmaceutical/Biotech Company, Immutep S.A. Clinical Trial Registration Number: NCT03625323. Efti + pembrolizumab is safe, showing encouraging antitumor activity in platinum and partially cetuximab pre-treated, 2nd line HNSCC patients. TACTI-003 (NCT04811027) a randomized study in 1st line HNSCC is currently recruiting. Response by iRECIST: Clinical trial information: NCT03625323.
P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • Erbitux (cetuximab) • ImmuFact (eftilagimod alpha)
over1year
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in patients with HER2-neg/low metastatic breast cancer receiving paclitaxel, following an open-label dose optimization. (ASCO 2023)
Key inclusion criteria: Pts with either a) HR+ and HER2-neg/low and endocrine therapy-resistant MBC or b) TNBC not eligible for anti-PD-1-based therapy. Pts must have measurable disease, ECOG PS 0-1 and no prior chemo for metastatic disease.
Clinical • P3 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
paclitaxel • ImmuFact (eftilagimod alpha)
over1year
AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization. (ESMO-BC 2023)
Key inclusion criteria: Pts with either a) HR+ and HER2-neg/low and endocrine therapy-resistant MBC or b) TNBC not eligible for anti-PD-1-based therapy. Pts must have measurable disease, ECOG PS 0-1 and no prior chemo for metastatic disease.
Clinical • P3 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
paclitaxel • ImmuFact (eftilagimod alpha)
over1year
Enrollment change • Trial withdrawal • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma)
|
ER positive • PGR positive
|
paclitaxel • ImmuFact (eftilagimod alpha)
over1year
Enrollment open • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HR negative • PGR positive
|
paclitaxel • ImmuFact (eftilagimod alpha)
almost2years
Molecular Correlates of Aggressive Behavior and Biologic Progression in Testicular Sertoli Cell Tumor. (PubMed, Mod Pathol)
The remaining 50% of metastasizing SCTs were CTNNB1-wild-type and harbored alterations in TP53, MDM2, CDKN2A/CDKN2B, and TERT pathways. These findings suggest that aggressive SCTs can arise from progression of CTNNB1-mutant benign SCTs, or from CTNNB1-wild type tumors with alterations of TP53, cell cycle regulation, and telomere maintenance pathways.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
TP53 mutation
almost2years
A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence. (PubMed, Acta Pharm Sin B)
Herein, a tactical nanomissile (TALE), equipped with a guidance system (PD-L1 monoclonal antibody), ammunition (mitoxantrone, Mit), and projectile bodies (tertiary amines modified azobenzene derivatives), is designed as a neoadjuvant chemo-immunotherapy setting, which aims at targeting tumor cells, and fast-releasing Mit owing to the intracellular azoreductase, thereby inducing immunogenic tumor cells death, and forming an in situ tumor vaccine containing damage-associated molecular patterns and multiple tumor antigen epitopes to mobilize the immune system...Moreover, this approach provokes a robust systemic immune response and immunological memory, as evidenced by preventing 83.3% of mice from postsurgical metastasis or recurrence in the B16-F10 tumor mouse model. Collectively, our results highlight the potential of TALE as a neoadjuvant chemo-immunotherapy paradigm that can not only debulk tumors but generate a long-term immunosurveillance to maximize the durable benefits of neoadjuvant chemotherapy.
Journal
|
CD8 (cluster of differentiation 8)
|
mitoxantrone
almost2years
The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies. (PubMed, Vaccines (Basel))
The usage of these substances in the treatment of solid tumors is being investigated. The present review discusses the direct and indirect influence that TLR7/8 agonists, such as imiquimod, imidazoquinolines and resiquimod have on neoplastic cells and their promising role as adjuvants in anticancer vaccines.
Review • Journal • IO biomarker
|
TLR8 (Toll Like Receptor 8)
|
Zyclara (imiquimod)
almost2years
New P2/3 trial • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HR negative • PGR positive
|
paclitaxel • ImmuFact (eftilagimod alpha)
almost2years
Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors (ELCC 2023)
Most common (>15%) adverse events were decreased appetite (33%), dyspnea (31%), cough (28%), asthenia (22%), fatigue (19%), arthralgia (17%) and weight decreased (17%). Conclusions Efti + pembrolizumab is safe and shows encouraging signs of antitumor activity in NSCLC pts resistant to PD-1/PD-L1 inhibitors, warranting further investigation.
P2 data • Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
almost2years
Role of adenomatous polyposis coli (APC) gene in SPOP-mutant prostate cancer and clinical outcomes. (ASCO-GU 2023)
In SPOPMT PCs, inactivation of APC is a common event and associated with more aggressive disease (higher metastatic potential and faster progression to castration resistance). This observation may help identify SPOPMT PC patients who are at higher risk for early castration resistance and could benefit from more intensive treatment.
Clinical data • Clinical
|
AR (Androgen receptor) • APC (APC Regulator Of WNT Signaling Pathway) • SPOP (Speckle Type BTB/POZ Protein)
|
APC mutation • SPOP mutation
|
Tempus xT Assay • Tempus xF Assay
2years
Use of high-dimensional and spatial immune profiling to explore sotigalimab (CD40 agonist) activation of antigen presenting cells and T cells in the tumor microenvironment in patients with esophageal/gastroesophageal junction cancer. (ASCO-GI 2023)
Sotiga induced dramatic changes in the tumor microenvironment including increased frequency of activated T cells and APCs, and decreased frequency of Tregs. A distinct signature of T cell infiltration in baseline tumor biopsies was observed in patients who achieved a pCR versus those who did not, potentially identifying patients that may benefit from this novel treatment strategy.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • ICOS (Inducible T Cell Costimulator) • CD40 (CD40 Molecule) • CD86 (CD86 Molecule)
|
CTLA4 expression • MHC-II expression
|
sotigalimab (PYX-107)
2years
Clinical • P1 data
|
CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3)
|
Bavencio (avelumab) • ImmuFact (eftilagimod alpha)
2years
Chromomycin A induces bona fide immunogenic cell death in melanoma. (PubMed, Front Immunol)
Some first-line cytotoxic chemotherapics, e.g. doxorubicin, paclitaxel and oxaliplatin, induce activation of the immune system through immunogenic cell death (ICD). Bona fide ICD induction by CA was confirmed by vaccination of C57BL/6 mice with CA-treated cells which activated antigen-presenting cells and T lymphocytes and stimulated antitumor activity. CA induces bona fide immunogenic cell death on melanoma.
Journal
|
HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin)
|
paclitaxel • doxorubicin hydrochloride • oxaliplatin
2years
Soluble LAG3 Primes T Cells to Attack NSCLC. (PubMed, Cancer Discov)
When combined with a PD-1 checkpoint inhibitor, the soluble LAG3 drug eftilagimod alpha activates antigen-presenting cells, offering deep and durable responses against non-small cell lung cancer. Even patients whose tumors express low levels of PD-L1 experienced an anticancer benefit.
Journal
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression
|
ImmuFact (eftilagimod alpha)
2years
Transdermal nanolipoplex simultaneously inhibits subcutaneous melanoma growth and suppresses systemically metastatic melanoma by activating host immunity. (PubMed, Nanomedicine)
Using lipoplex (Lipo-PEG-PEI-complex, LPPC) encapsulated doxorubicin (DOX) and carrying CpG oligodeoxynucleotide; the transdermally administered nano-liposomal drug complex (LPPC-DOX-CpG) would have high cytotoxicity and immunostimulatory activity to suppress systemic metastasis of melanoma...Furthermore, NGS analysis revealed IFN-γ and NF-κB pathways were triggered to recruit and activate the antigen-presenting-cells and effecter cells, which could activate the anti-tumor responses as the major mechanism responsible for the therapeutic effect of LPPC-DOX-CpG. Finally, we have successfully proved transdermal LPPC-DOX-CpG as a promising penetrative carrier to activate systemic anti-tumor immunity against subcutaneous and metastatic tumor.
Journal
|
IFNG (Interferon, gamma)
|
doxorubicin hydrochloride
2years
Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II) (SITC 2022)
P2 | "Early & sustained increases of circulating CXCL-10 & IFN-gamma levels were observed. Conclusions E + P is safe & shows encouraging antitumor activity in 1st line metastatic NSCLC patients unselected for PD-L1, warranting late-stage clinical investigation."
Late-breaking abstract • P2 data • Clinical
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CD4 (CD4 Molecule)
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
2years
Quercetin-ferrum nanoparticles enhance photothermal therapy by modulating the tumor immunosuppressive microenvironment. (PubMed, Acta Biomater)
The QFN-PTT-treated mice exhibited significantly elongated survival time, and gained strong anti-tumor immune memory to prevent tumor metastasis and recurrence. Thus, this work provided a simple and versatile photothermic agent, and it has important implications for designing effective and translationally feasible photosensitizers for PTT.
Journal
|
PD-L1 (Programmed death ligand 1) • STAT3 (Signal Transducer And Activator Of Transcription 3)